- Home
- WNEB vs AVTX Comparison
WNEB vs AVTX Comparison
Compare WNEB & AVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | WNEB | AVTX |
|---|---|---|
| Founded | 1853 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 270.5M | 248.3M |
| IPO Year | N/A | 2015 |
Fundamental Metrics
Financial Performance| Metric | WNEB | AVTX |
|---|---|---|
| Price | $14.16 | $14.60 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 10 |
| Target Price | $11.00 | ★ $34.50 |
| AVG Volume (30 Days) | 56.2K | ★ 364.8K |
| Earning Date | 01-27-2026 | 03-19-2026 |
| Dividend Yield | ★ 2.01% | N/A |
| EPS Growth | ★ 34.36 | N/A |
| EPS | ★ 0.75 | N/A |
| Revenue | ★ $82,278,000.00 | $192,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $5.32 | N/A |
| P/E Ratio | $18.61 | ★ N/A |
| Revenue Growth | ★ 12.12 | N/A |
| 52 Week Low | $7.63 | $3.39 |
| 52 Week High | $14.00 | $20.72 |
Technical Indicators
Market Signals| Indicator | WNEB | AVTX |
|---|---|---|
| Relative Strength Index (RSI) | 71.61 | 39.69 |
| Support Level | $13.02 | $14.63 |
| Resistance Level | $13.80 | $16.80 |
| Average True Range (ATR) | 0.38 | 1.05 |
| MACD | 0.12 | -0.01 |
| Stochastic Oscillator | 87.43 | 7.31 |
Price Performance
Historical ComparisonAbout WNEB Western New England Bancorp Inc.
Western New England Bancorp Inc through its bank subsidiary, provides a range of financial services to individuals and companies in western Massachusetts and northern Connecticut. These services include commercial lending, residential lending and consumer lending, checking, savings and time deposits, cash management, and wealth management. Substantially all of the company's revenues, profits, and assets are derived by the Bank from banking products and services.
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).